REGENXBIO Inc. (RGNX) |
16.04 0.14 (0.88%) 04-24 16:00 |
Open: | 15.96 |
High: | 16.39 |
Low: | 15.6 |
Volume: | 334,414 |
Market Cap: | 786(M) |
PE Ratio: | -2.66 |
Exchange: | NASDAQ Global Select |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 23.14 |
Resistance 1: | 20.10 |
Pivot price: | 17.63 |
Support 1: | 15.18 |
Support 2: | 12.63 |
52w High: | 28.8 |
52w Low: | 11.83 |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
EPS | -6.020 |
Book Value | 7.080 |
PEG Ratio | -0.26 |
Gross Profit | 0.000 |
Profit Margin (%) | -291.99 |
Operating Margin (%) | -271.03 |
Return on Assets (ttm) | -23.5 |
Return on Equity (ttm) | -63.7 |
Tue, 23 Apr 2024
Raymond James & Associates Decreases Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Wed, 17 Apr 2024
REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take ... - Yahoo Finance
Sun, 14 Apr 2024
Institutional owners may consider drastic measures as REGENXBIO Inc.'s (NASDAQ:RGNX) recent US$53m drop adds ... - Simply Wall St
Fri, 08 Mar 2024
Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares - Yahoo Finance
Thu, 07 Mar 2024
Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates - Yahoo Finance
Wed, 06 Mar 2024
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study - Zacks Investment Research
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |